Key Principles from the 2024 AUA Guidelines Updates on Salvage Prostate Cancer Therapy
Justin J. Badal, MD, reviews the updated 2024 guidelines for advanced prostate cancer, reflecting substantial advancements since the last revision in 2013. The revision synthesizes evidence from numerous trials to reshape recommendations, focusing particularly on treatment strategies for biochemical recurrence (BCR) following radical prostatectomy.
In this 18-minute presentation, Badal shares guidelines emphasizing utilizing prognostic factors, such as PSA doubling time and Gleason grade, to stratify patient risk and guide treatment timing. He notes that ultra-sensitive PSA testing for high-risk individuals and PET imaging, particularly PSMA PET scans, is recognized as valuable tools for detecting biochemical recurrence.
The integration of androgen deprivation therapy (ADT) with SRT is advised for patients showing high-risk features, while, for those without high-risk markers, radiation monotherapy remains an option. For recurrent or node-positive cases post-primary therapy, combined modality approaches, including the use of expanded radiation fields and intensified androgen receptor suppression, are encouraged within a clinical trial setting.
Read More